By Colin Kellaher

 

Replimune Group Inc. on Tuesday said it inked a deal to work with Swiss pharmaceutical company Roche Holding AG to advance Replimune RP2/3 program in colorectal cancer and hepatocellular carcinoma.

Replimune said Roche would share costs to develop RP3 in combination with Roche's cancer drugs Tecentriq and Avastin in third-line colorectal cancer and in second-line hepatocellular carcinoma.

Replimune, a Woburn, Mass., clinical-stage biotechnology company, said Roche would also supply Tecentriq and Avastin for combination studies of RP3 in first-line hepatocellular carcinoma and RP2 in third-line colorectal cancer.

Replimune, which has similar collaborations in place for its lead candidate RP1 with Regeneron Pharmaceuticals Inc. and Bristol Myers Squibb Co., said it is on track to initiate its Phase 2 development program with RP2/3 in the first half of 2023.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

December 07, 2022 07:29 ET (12:29 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Replimune (NASDAQ:REPL)
Historical Stock Chart
From Dec 2022 to Jan 2023 Click Here for more Replimune Charts.
Replimune (NASDAQ:REPL)
Historical Stock Chart
From Jan 2022 to Jan 2023 Click Here for more Replimune Charts.